|
Mechanismfungal CYP51A1 inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date25 Oct 2005 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date04 Jun 1986 |
|
MechanismCSF-2R stimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.SE |
First Approval Date08 Nov 1991 |
100 Clinical Results associated with Schering-Plough Europe SA
0 Patents (Medical) associated with Schering-Plough Europe SA
100 Deals associated with Schering-Plough Europe SA
100 Translational Medicine associated with Schering-Plough Europe SA